HIV-1 integrase binds site-specifically to the ends of the viral cDNA. We used two HIV-1 integrase-DNA cross-linking assays to probe the binding sites of integrase inhibitors from different chemical families and with different strand transfer selectivities. The disulfide assay probes cross-linking between the integrase residue 148 and the 5Ј-terminal cytosine of the viral cDNA, and the Schiff base assay probes cross-linking between an integrase lysine residue and an abasic site placed at selected positions in the viral cDNA. Cross-linking interference by eight integrase inhibitors shows that the most potent cross-linking inhibitors are 3Ј-processing inhibitors, indicating that crosslinking assays probe the donor viral cDNA (donor binding site). In contrast, strand transfer-selective inhibitors provide weak cross-linking interference, consistent with their binding to a specific acceptor (cellular DNA) site. Docking and crystal structure studies illustrate specific integrase-inhibitor contacts that prevent cross-linking formation. Four inhibitors that prevented Schiff base cross-linking to the conserved 3Ј-terminal adenine position were examined for inhibition at various positions within the terminal 21 bases of the viral cDNA. Two of them selectively inhibited upper strand cross-linking, whereas the other two had a more global effect on integrase-DNA binding. These findings have implications for elucidating inhibitor binding sites and mechanisms of action. The cross-linking assays also provide clues to the molecular interactions between integrase and the viral cDNA.
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HIV-1 integrase is required for insertion of the viral cDNA into host chromosomes. Integrase catalyzes this insertion in two steps. First, an endonucleolytic reaction cleaves both ends of the viral cDNA immediately 3Ј from a conserved CA dinucleotide sequence (underlined in Fig. 1A ). This releases a terminal 5Ј-GT dinucleotide from the end of each viral long terminal repeat (LTR) in a reaction called 3Ј-processing (3Ј-P). Subsequently, the viral and host DNAs are joined by insertion of both nucleophilic viral cDNA 3Ј-hydroxyl ends into a host chromosome (termed strand transfer, ST) (Lewinski and Bushman, 2005; Pommier et al., 2005; Van Maele and Debyser, 2005; Marchand et al., 2006) . Despite many attempts, no crystal structure of integrase bound to its DNA substrates has been resolved. Nevertheless, several specific interactions between the viral cDNA and integrase have been revealed biochemically. The deoxyadenosine of the conserved 5Ј-CA motif immediately 5Ј to the 3Ј-P site (referred to as 3Ј-A; see Fig. 1A ) contacts integrase near residue Lys-159 as shown by photocross-linking of a substituted 5-iododeoxyuracil at this position (Jenkins et al., 1997) . A crystal structure of integrase suggested that Lys-159 also contacts the phosphate 5Ј to the conserved 3Ј-A (Wang et al., 2001 ). Photocross-linking indicated contacts between integrase residues Tyr-143 and Gln-148 and the adenine at the 5Ј-end of the uncleaved strand (Esposito and Craigie, 1998) . We have reported, after using disulfide cross-linking, the proximity of the integrase amino acid residue 148 (mutated from glutamine to cysteine) to the second base (referred to as the 5Ј-C) from the 5Ј end of the "lower strand" of the duplex (thiol-modified C; see Fig. 1A ) (Gao et al., 2001; Johnson et al., 2006a) . Given the lack of cocrystal structures, such information is important for understanding interactions between integrase and the viral cDNA.
Many integrase inhibitors have been discovered during the past 10 years, with two of them presently in clinical trials (for review, see Pommier et al., 2005; Dayam et al., 2006; DeJesus et al., 2006; Semenova et al., 2006b) . The binding sites of only two inhibitors, 5CITEP and Y-3, have been determined by X-ray crystallography (Lubkowski et al., 1998; Goldgur et al., 1999) . Integrase inhibitors can be classified as those that inhibit both 3Ј-P and ST reactions (defined as 3Ј-P inhibitors) and those that inhibit ST efficiently but have little or no effect on 3Ј-P (defined as ST-selective inhibitors). ST-selective inhibitors, such as diketo acid and naphthyridine carboxamide derivatives (Hazuda et al., 2000 (Hazuda et al., , 2004a , have been proposed to bind at the interface of the integrase-DNA complex . As part of our ongoing effort to characterize the molecular interactions between integrase, inhibitors, and the U5 LTR viral cDNA end (Johnson et al., 2004 , here we describe the use of disulfide and Schiff base cross-linking (Mazumder et al., 1996) to examine interference upon cross-link formation of various integrase inhibitors.
For the disulfide cross-linking assay, we used site-directed mutagenesis to create a Gln-148-Cys integrase mutant that forms a disulfide cross-link with the 5Ј-C of the U5 LTR ) (see Fig. 1 ). Integrase-mediated 3Ј-P releases a terminal 5Ј-GT dinucleotide, resulting in a 5Ј-AC overhang. This overhang is required for ST (Bushman and Craigie, 1992) . We recently proposed that a hydrogen bond between integrase Gln-148 and the 5Ј-C is required for ST in the presence of magnesium . Because the two interacting groups [residue 148 of integrase and the second base from the 5Ј end of the LTR (the 5Ј-C)] are defined, we reasoned that valuable information could be obtained about drug binding site(s) from interference of protein/DNA interactions in the presence of inhibitors .
To further examine drug-DNA interactions with integrase, we also used a Schiff base cross-linking assay by inserting a reactive abasic site at various positions within the viral cDNA substrate (Mazumder et al., 1996) . A covalent linkage between an integrase lysine residue and the amino-reactive abasic site (generated by uracil DNA glycosylase) enables formation of a Schiff base that can be reduced by sodium borohydride (Mazumder et al., 1996) (Fig. 1C) . The position of the abasic site can be varied to examine cross-link positional effects. The position of the cross-linking lysines can be estimated from structural and molecular modeling studies.
We demonstrate that potent 3Ј-P inhibitors are also the most potent cross-linking inhibitors, whereas ST-selective inhibitors such as L-708,906 (Hazuda et al., 2000) and L-870,810 (Hazuda et al., 2004a) are weak inhibitors of crosslinking. Inhibition of the specific contacts required for disulfide and Schiff base cross-linking is supported by inhibitorintegrase contacts identified through crystal structures and docking studies for several inhibitors. Results from the Schiff base cross-link assays using an abasic site at defined positions suggest that 3Ј-P inhibitors interfere with the binding of integrase at sites distal from the active site. The findings reported here indicate the value of cross-linking assays to gain insight into inhibitor binding sites and interactions between integrase and the viral cDNA.
Materials and Methods
Oligonucleotide Synthesis. Unmodified and uracil-containing (for Schiff base cross-linking studies) oligonucleotides were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA). For (Mazumder et al., 1996; Johnson et al., 2006a) and inhibition by the integrase inhibitor, bis-DKA Pais et al., 2002) . A, schematic diagram illustrating disulfide crosslink formation between a thiol-modified cytosine and an integrase Gln-148-Cys mutant. The star indicates the position of 32 P labeling. B, representative gel showing inhibition of disulfide cross-link formation by the bis-DKA inhibitor (see chemical structure in Fig. 4 (Ferentz and Verdine, 1991) , and the resulting cystaminemodified oligonucleotide was gel-purified. The cystamine was reduced with 100-fold molar excess of DTT for 20 min at 37°C and purified using a mini Quickspin Oligo column (Roche, Indianapolis, IN). The thiol modification was activated by the addition of a 10-fold molar excess of 5,5Ј-dithiobis(2-nitrobenzoic acid) in phosphate buffer, pH 8.5, for 1 h at 37°C. The activated DNA was purified by a mini Quickspin Oligo column (Roche, Indianapolis, IN).
All oligonucleotides were purified on denaturing 20% polyacrylamide gels. Single-stranded oligonucleotides were 5Ј-labeled using T4 polynucleotide kinase (Invitrogen, Carlsbad, CA) with [␥- 32 P]ATP (PerkinElmer Life and Analytical Sciences, Boston, MA) according to the manufacturers' instructions. Unincorporated nucleotides were removed by mini Quickspin Oligo columns (Roche). The duplex DNA was annealed by addition of an equal concentration of the complementary strand, heating to 95°C, and slow cooling to room temperature.
Inhibitors. L-708,906, L-870,810, 5CITEP, bis-DKA and L-chicoric acid were synthesized as described previously Lin et al., 1999; Anthony et al., 2002; Pais et al., 2002; Hazuda et al., 2004a) . Compounds RDS-1997 and RDS-1625 were synthesized by the Di Santo group (Di Santo et al., 2005 Santo et al., , 2006 . Conocurvone was obtained as a gift from Dr. Jonathan Coates of AMRAD Operations Pty Ltd (Victoria, Australia). All drug solutions were prepared from powder in 100% dimethyl sulfoxide. Drug concentrations producing 50% inhibition (IC 50 values, Table 1 ) are from previous reports Di Santo et al., 2006; Johnson et al., 2006b; Stagliano et al., 2006) or were determined as described below. Note that all the compounds shown display anti-HIV activity, except for bis-DKA and 5CITEP (summarized with references in Table 1 ).
Production of Recombinant Integrase. Recombinant wildtype HIV-1 integrase was purified from E. coli as described previously (Leh et al., 2000) with the addition of 10% glycerol to all buffers. Wild-type integrase was used for Schiff base and standard catalytic assays. Site-directed mutagenesis was used to create the integrase mutant Q148C/C56S/C65S/C280S ["QSSS," described previously by Johnson et al. (2006a) ] for disulfide cross-linking. The three cysteine-to-serine mutations provide a cross-linking-free background before the addition of the desired cysteine at position 148 . The QSSS mutant was purified using the same method as wild type but with the omission of reducing agents from all buffers after bacterial lysis.
Schiff Base Cross-Linking Assay. Oligonucleotides containing a single uracil at the indicated positions (see Fig. 5 ) were 5Ј-[ 32 P]-labeled as described above. After annealing, uracil DNA glycosylase was added to create an abasic site at the uracil position. The abasic site forms a Schiff base cross-link between the deoxyribose aldehyde group and a nearby integrase lysine.
The Schiff base cross-linking experiments were performed as described previously (Mazumder et al., 1996) . Inhibitors were preincubated for 20 min at room temperature with 500 nM wild-type integrase, 7.5 mM MgCl 2 , 14 mM 2-mercaptoethanol, and 20 mM MOPS, pH 7.2. Abasic-site containing duplex DNA (final concentration, 20 nM) was added to each reaction and incubated at room temperature for 5 min. The cross-links were reduced by adding 100 mM sodium borohydride (final concentration) before the addition of tricine-SDS gel loading buffer (1ϫ final concentration). The cross-linked integrase-DNA products were separated from the substrate DNA by SDS-PAGE using 16% tricine gels (Invitrogen, Carlsbad, CA).
Disulfide Cross-Linking. Q148C/SSS integrase (500 nM) was incubated with inhibitors in the presence of 20 mM Tris, pH 7.4, 7.5 mM MgCl 2 and 10% glycerol for 20 min at room temperature. DNA duplexes (20 nM) containing a 5Ј-32 P label on the "upper strand" and a thiol-modified cytosine on the other strand (see Fig. 1A ) were added to each reaction. The thiol-activated DNA was not labeled itself to avoid reduction of the thiol modification during the labeling reaction. After 2 min, reactions were capped by the addition of 20 mM methylmethanethiosulfonate (MMTS). Nonreducing gel loading buffer (100 mM Tris-Cl, pH 6.8, 4% SDS, 0.2% bromphenol blue, and 20% glycerol) was added and samples were loaded directly onto 16% polyacrylamide gels (Invitrogen). Dried gels were visualized using a 445 SI PhosphorImager (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Quantitation was performed by densitometric analysis using the ImageQuant software from GE Healthcare.
Integrase Reactions. Integrase was incubated with DNA substrates for 20 min on ice. The reaction conditions were 500 nM integrase, 20 nM duplex DNA, 7.5 mM MgCl 2 , 5 mM NaCl, 14 mM 2-mercaptoethanol, and 20 mM MOPS, pH 7.2. Nine microliters of integrase-DNA mixture was aliquoted into tubes containing 1 l of inhibitor, and the reactions proceeded at 37°C for 1 h. Reactions were quenched by the addition of an equal volume of gel loading dye (formamide containing 1% SDS, 0.25% bromphenol blue, and xylene cyanol). Products were separated on 20% polyacrylamide denaturing sequencing gels. Dried gels were visualized using a 445 SI PhosphorImager (GE Healthcare). Densitometric analysis was performed using ImageQuant software from GE Healthcare.
Statistical Analysis. Correlations between inhibition of the two cross-linking assays and integrase catalytic assays were examined using one-tailed Pearson's correlation coefficients for each compari- Marchand et al. (2002) . b Hazuda et al. (2000) . c Hazuda et al. (2004b) . d Pais et al. (2002) . e Di Santo et al. (2005 Santo et al. ( , 2006 . f Stagliano et al. (2006) . g Decosterd et al. (1993) . i IC 50 values for 3Ј-P and ST were obtained in the presence of manganese ). 
Results
Inhibition of Disulfide Cross-Link Formation by Integrase Inhibitors. The assay is based on the formation of a disulfide bond between residue 148 (Gln-148-Cys mutant) within the integrase catalytic core domain and a thiol-modified cytosine located at the tip (5Ј-C) of the HIV LTR (Fig. 1A) . We recently reported the functional importance of this interaction, and proposed that a hydrogen bond between integrase Gln-148 and the 5Ј-C is required for ST in the presence of magnesium . The cross-linking complexes between integrase and the 32 P-labeled-DNA are observed as a ladder of oligomeric integrase products in nonreducing SDS-PAGE gels (Fig. 1B) . Figure 1B demonstrates inhibition of disulfide cross-linking by the bis-DKA derivative (see chemical structure in Fig. 4) , which acts as a potent 3Ј-P inhibitor (inhibitor of both 3Ј-P and ST; see Introduction) .
Inhibition of Schiff Base Formation by Integrase Inhibitors. The Schiff base-mediated cross-linking assay detects covalent bonds between integrase and a DNA abasic site substitution. In the experiment shown in Fig. 1 , the abasic site is placed at the position of the conserved adenine of the HIV LTR (Mazumder et al., 1996) (Fig. 1C) . The 3Ј-side of the adenine is the site of 3Ј-P, providing the 3Ј-OH nucleophile required for ST. The formation of an integrase-DNA complex is observed as a band with retarded migration in SDS-PAGE gels (Fig. 1D) (Mazumder et al., 1996) . Figure 1D shows inhibition of Schiff base cross-linking by the bis-DKA.
Integrase Inhibition Activities of L-870,810. Integrase ST-selective inhibitors are being pursued for clinical development (Hazuda et al., 2004a,b; Pommier et al., 2005; Dayam et al., 2006; DeJesus et al., 2006; Semenova et al., 2006a) . The naphthyridine carboximide L-870,810 ( Fig. 2A) has been reported as a highly ST-selective inhibitor (Hazuda et al., 2004a) . However, actual inhibition experiments have never been reported. Figure 2 (B and C) shows that L-870,810 is indeed a potent ST-selective inhibitor. IC 50 values for ST and 3Ј-P are 0.06 and Ͼ12.3 M, respectively, giving a selectivity ratio of at least 200-fold (Fig. 2C and Table 1 ). Figure 2 also shows that L-870,810 is a weak inhibitor in both disulfide and Schiff base cross-linking assays (D and E, respectively). The contrast between the results obtained with L-870,810 and the bis-DKA suggests that ST-selective inhibitors produce minimal interference with viral cDNA binding as determined by cross-linking inhibition assays.
Integrase Inhibition Activities of RDS-1625. The monofunctional diketo acid RDS-1625 (Fig. 3A) is structurally related to the previously reported bifunctional DKA RDS-1997 (Di Santo et al., 2006 ) (see Fig. 4 ). Both compounds are potent ST inhibitors (Di Santo et al., 2006) (Fig.  3 , B and C, and Table 1 ). However, the second DKA group of RDS-1997 also provides potent inhibition of 3Ј-P (Di Santo et al., 2006) whereas RDS-1625 has a 70-fold selectivity for ST (Fig. 3 , B and C, and Table 1 ). Consistent with the results obtained for L-870,810 (see Fig. 2 ), we find that RDS-1625 is a weak inhibitor of either disulfide or Schiff base crosslinking assays (Fig. 3, D and E) , suggesting the ST-selective inhibitor RDS-1625 may bind in a similar region as L-870,810.
Comparison of Different Inhibitors in the Disulfide and Schiff Base Cross-linking Assays. Eight integrase inhibitors from different families and with differential selectivity for ST and 3Ј-P were evaluated in the disulfide and Schiff base cross-linking assays. Figure 4 shows the doseresponse curves, and Table 1 summarizes the IC 50 values for inhibition of 3Ј-P, ST, disulfide, and Schiff base cross-linking.
The most ST-selective inhibitors include the DKA derivative L-708,906 (Hazuda et al., 2000 (Hazuda et al., , 2004b Grobler et al., 2002; Marchand et al., 2002 Marchand et al., , 2003 Pais et al., 2002) , the naphthy- (Fig. 2) (Hazuda et al., 2004a) , RDS-1625 (Fig. 3) , and, to a lesser extent, RDS-1997 (Di Santo et al., 2006 . The 3Ј-P inhibitors (dual inhibitors of ST and 3Ј-P, Table 1 ) include conocurvone (Stagliano et al., 2006) , L-chicoric acid (King et al., 1999; Pais et al., 2002) , bis-DKA Marchand et al., 2003) , and 5CITEP Marchand et al., 2003) . Indeed the ST-selectivity of 5CITEP is markedly reduced when the divalent metal cofactor is switched from Mn 2ϩ to Mg 2ϩ (Marchand et al., 2003) . As described previously in Fig. 1 , the bis-DKA is a relatively potent inhibitor of both cross-link assays (Fig. 4, A and  B, ᭹) . By contrast, 5CITEP is a potent inhibitor of the disulfide cross-link (Fig. 4A, ࡗ) ) and a relatively weak inhibitor of Schiff base cross-linking (Fig. 4B,  ࡗ) . In comparison, L-708,906 (Fig. 4, A and B, ƒ) and L-870,810 (Fig. 4, A and B, Ⅺ) are weak inhibitors of both disulfide and Schiff base cross-linking assays. Therefore, the DKA and naphthyridine carboxamide derivatives illustrate differences in cross-linking inhibition among the ST-selective inhibitors.
The DKA RDS-1997 (Fig. 4 , C and D, F) containing two diketo acid moieties (similar to the bis-DKA) inhibits both disulfide and Schiff base cross-linking efficiently compared with RDS-1625 (Fig. 4 , C and D, Ⅺ), which contains only one DKA moiety. Thus, addition of a second DKA group (as in bis-DKA and RDS-1997) provides interactions between integrase and the viral cDNA as determined by cross-linking inhibition.
Finally, 3Ј-P inhibitors (dual inhibitors of ST and 3Ј-P) showed drug-specific differences. The synthetic dicaffeoyl derivative L-chicoric acid (L-CA) King et al., 1999; Lin et al., 1999) (Fig. 4, E and F, f) is the most potent inhibitor of disulfide cross-linking among the eight compounds examined (compare E, C, and A in Fig. 4 ; Table  1 ). L-CA is also among the most potent inhibitors of Schiff base cross-link formation. The natural product conocurvone (Stagliano et al., 2006) (Fig. 4, E and F, ‚) is a relatively potent inhibitor of disulfide cross-link formation and a weaker inhibitor of Schiff base cross-linking.
Effects of Schiff Base Cross-Linking Position within the Substrate DNA. First, we scanned the integrase-DNA contacts in the absence of drug using different Schiff base substrates containing a single abasic site at various positions. Figure 5A summarizes multiple experiments where cross-linking efficiency was examined over the indicated positions of the terminal 21 base pairs of the U5 LTR DNA. In the absence of drug, cross-linking to the "top" strand of the duplex results in two cross-linking peaks at the 3rd and 14th positions from the end of the viral cDNA (Fig. 5A, F) . Crosslinking to the "bottom" strand (⅜) is weaker in general, and results in maximum cross-linking at the 8th position. The highest efficiency sites for each strand (top 3 and 14 and bottom 8) lie on the same side of a double helix in standard B-form DNA and the lysines likely to interact with each cross-link position are noted in Fig. 5B (Karki et al., 2004) .
The three positions giving maximum cross-linking (top 3, top 14, and bottom 8) plus the 19th position of the bottom strand (Fig. 5, A and B) were then used to examine Schiff base cross-linking inhibition as a function of the cross-linking position. The drugs producing inhibition of Schiff base crosslinking at the 3rd position (RDS-1997, RDS-1625, bis-DKA, and L-chicoric acid; see Figs. 1-4) were tested for inhibition of Schiff base cross-linking at these four positions (Fig. 5) . RDS-1997 and RDS-1625 inhibit Schiff base cross-linking more effectively at the top 3rd and 14th positions (Fig. 5, C and D; and F, respectively) compared with the bottom 8th and 19th positions (Fig. 5 , C and D; छ and Ⅺ, respectively). This differential inhibition was not observed with bis-DKA or L-chicoric acid (Fig. 5, E and F) . These results suggest that RDS-1997 and RDS-1625 tend to interfere preferentially with upper strand cross-linking, whereas L-chicoric acid and bis-DKA inhibit overall viral cDNA binding.
Comparison of 3-P and ST Inhibition and CrossLinking Inhibition for Integrase Inhibitors. Figure 6 shows graphical comparisons of inhibition parameters to highlight differences in inhibitor potencies. A is a plot of the 3Ј-P versus ST IC 50 values for the eight compounds tested. Conocurvone and L-chicoric acid show no selectivity for ST and therefore sit on the X ϭ Y line (3Ј-P ϭ ST). By contrast, L-870,810 is the most ST-selective inhibitor studied (see Fig.  2 and Table 1) , and is the furthest from the X ϭ Y line. The novel DKA derivative RDS-1997 is the most potent inhibitor of ST (IC 50 of 0.02 M) but is also one of the most potent inhibitors of 3Ј-P (IC 50 of 0.4 M; see Fig. 2 and Table 1 ). The ratio for 3Ј-P/ST selectivity is listed in Table 1 , where a high value indicates true ST-selectivity.
The plot of Schiff base versus disulfide cross-linking inhibition (Fig. 6B) illustrates an overall positive correlation between inhibition of Schiff base and disulfide cross-linking for the eight compounds studied (r ϭ 0.73, p Ͻ 0.05). Lchicoric acid is the best inhibitor in both assays, whereas L-708,906 and L-870,810 fail to block either cross-linking reaction effectively. L-chicoric acid, RDS-1997, conocurvone, and 5CITEP inhibit disulfide cross-linking at least 10 times more efficiently than Schiff base cross-linking (Fig. 6B) .
Pair-wise comparisons for inhibition of cross-linking (in each of the two assays) versus inhibition of integrase reactions (3Ј-P and ST) are shown in Fig. 6 , C to F. Potent 3Ј-P inhibitors (L-chicoric acid, RDS-1997, and conocurvone) effectively blocked viral cDNA binding (cross-linking), whereas ST-selective inhibitors with weak inhibition of 3Ј-P (L-708,906 and L-870,810) had minimal effect on viral cDNA binding.
Discussion
Inhibition of integrase-DNA cross-linking demonstrates interference with viral cDNA binding. In particular, inhibition of disulfide cross-linking indicates that an inhibitor prevents the normal interaction between the integrase 148 residue and the conserved 5Ј-cytosine (5Ј-C) two bases from the end of the viral cDNA . Inhibition of crosslinking via Schiff base formation at an abasic site placed at the A position of the conserved CA (3Ј-A, position top 3 in Fig.  5B) indicates that an inhibitor blocks bond formation between integrase residues and the DNA at the 3rd position from the end of the viral cDNA. Because the 3Ј-A and 5Ј-C belong to adjacent base pairs, cross-linking assays can be used together to probe drug binding sites with precision. Moreover, because both contacts are important for specific recognition of the viral LTR cDNA end and integrase activity (Mazumder and Pommier, 1995; Johnson et al., 2006a) , it is plausible that alteration of these interactions is the primary mechanism of action for 3Ј-P inhibitors such as L-chicoric acid, bis-DKA, conocurvone, and RDS-1997 (see Fig. 6B ).
L-Chicoric acid is the most potent inhibitor of disulfide cross-linking, with approximately 50-fold selectivity for disulfide over Schiff base cross-linking (Fig. 6B, Table 1 ). Consistent with this result, docking experiments suggest that L-chicoric acid forms a hydrogen bond with Gln-148 (Sotriffer et al., 2000) . Moreover, HIV in cell culture gains a Gly-140-Ser resistance mutation when cultured with L-chicoric acid for extended periods (King and Robinson, 1998) . The finding that L-chicoric acid also inhibits Schiff base cross-linking with the conserved 3Ј-A is also consistent with docking experiments showing interactions of chicoric acid with Lys-156 and Lys-159 (Sotriffer et al., 2000) . Because L-chicoric acid inhibits Schiff base cross-linking irrespective of the position of the abasic site from the end of the viral cDNA (Fig. 5E) , it is likely that L-chicoric acid binds near residues ranging from Bis-DKA is a 3Ј-P inhibitor that inhibits both the integrase 3Ј-P and ST reactions ( Fig. 6A and Table 1 ) , as well as both disulfide and Schiff base cross-linking within the same concentration range (Fig. 6B) . We also find that bis-DKA inhibits Schiff base cross-linking over several positions of the viral cDNA (Fig. 5F ). In agreement with these results, bis-DKA has been proposed to interfere with both the acceptor and donor DNA binding sites of integrase . Docking of bis-DKA to an integrase-DNA-Mg 2ϩ complex suggests that bis-DKA extends from the metal chelation site toward the viral LTR conserved 3Ј-A (Marchand et al., 2003) . Together, these results suggest that bis-DKA, like L-chicoric acid, has a global effect on integrase-DNA binding.
5CITEP is one of two integrase inhibitors cocrystallized with integrase (Lubkowski et al., 1998; Goldgur et al., 1999) . 5CITEP is a ST-selective inhibitor in the presence of Mn 2ϩ . However, this selectivity is markedly reduced in the presence of Mg 2ϩ (Table 1 ) (Marchand et al., 2003) . 5CITEP was cocrystallized in the integrase catalytic site in the absence of donor DNA (Goldgur et al., 1999) . In this cocrystal, 5CITEP contacts Gln-148 of the integrase flexible loop (Greenwald et al., 1999) . As 5CITEP inhibits cross-linking of this same amino acid residue 148 in our disulfide cross-linking assay (Fig. 4A) , contacts between 5CITEP and the flexible loop probably play an important role for the integrase inhibition. 5CITEP also exhibits approximately 22-fold selectivity for disulfide cross-linking inhibition over Schiff base cross-linking inhibition with the abasic site placed at the conserved 3Ј-A position (Fig. 6B ). Because the 3Ј-A position corresponds to the base pair adjacent to the 5Ј-C, these results suggest that 5CITEP binds near the 5Ј-C and Gln-148 of integrase but has only minor interaction with the 3Ј-A and Lys-159/ 156. Such a selective inhibition of disulfide cross-linking versus Schiff base cross-linking is consistent with the cocrystal structure (Goldgur et al., 1999) .
Conocurvone is a dual inhibitor of 3Ј-P and ST with antiviral activity (Stagliano et al., 2006) . We find that conocurvone inhibits disulfide cross-linking in the same concentration range as for 3Ј-P and ST inhibition (Fig. 6 , A and C, and Table 1 ). Because conocurvone exhibits an approximately 20-fold selectivity for disulfide versus Schiff base cross-linking, it is likely that conocurvone preferentially interferes with and inhibits the contacts between integrase Gln-148 and the terminal 5Ј-C of the viral cDNA. As conocurvone inhibits 3Ј-P, it is a candidate for cocrystallization with the core domain of integrase.
Among the diketo acid derivatives, RDS-1997 is the only compound with significant cross-linking inhibition (Fig. 6B) . RDS-1997 is also the most potent inhibitor of both 3Ј-P and ST (Fig. 6A) (Di Santo et al., 2006) . Docking with integrase suggests that RDS-1997 interacts with Lys-156 and Lys-159 (Di Santo et al., 2006) , the lysines that are thought to form Schiff base cross-linking with the abasic site substitution at the conserved 3Ј-A position. Scanning of Schiff base crosslinking inhibition with RDS-1997 showed strongest inhibition when the abasic site is placed at the 3Ј-A position (Fig.  5C ). Hence, we propose that RDS-1997 binds near and interacts with Lys-156/159. Because RDS-1997 is an effective 3Ј-P inhibitor with remarkable inhibition of Schiff base crosslinking at the 3Ј-A position, this compound might be a good candidate for cocrystallization with the integrase core domain.
The ST-specific inhibitors L-870,810 and L-708,906 dock within the integrase active site by extending away from the region containing Lys-156 and Lys-159 Marchand et al., 2003; Hazuda et al., 2004a) . This is probably the case for RDS-1625, which is also a ST-specific inhibitor (Figs. 3 and 6A ). All three compounds are weak inhibitors of cross-linking both in the disulfide and Schiff base assays (Fig. 6B) . They may bind the integrase-DNAmetal complex in an orientation that does not interfere with viral DNA binding and 3Ј-P. Selective inhibitors of ST are therefore inefficient cross-link inhibitors because they may have a separate set of binding interactions, such as with the acceptor DNA site and integrase, enabling specificity for ST inhibition. Thus, it is possible that L-708,906, L-870,810, and RDS-1625 prevent ST by blocking acceptor DNA binding.
The experiments presented here provide novel information for drug binding sites in the integrase-viral cDNA complex. In the absence of integrase-DNA and integrase-inhibitor cocrystal structures, the cross-linking inhibition analyses provide unique tools to probe drug binding interactions and mechanistic understanding of integrase inhibition by various classes of drugs.
